Publications by authors named "L S Havel"
Article Synopsis
- IMbrella A is a Phase III study that allowed patients from earlier atezolizumab trials, like IMpower133, to continue receiving treatment for extensive-stage small cell lung cancer (SCLC) with atezolizumab plus chemotherapy after the initial trials closed.
- In IMbrella A, 18 out of 26 eligible patients rolled over for further treatment, and results showed that median follow-up was 59.4 months with estimated three-, four-, and five-year overall survival rates of 16%, 13%, and 12%, respectively.
- The study reported that 16.7% of patients experienced serious adverse events, with only one grade two hypothyroidism noted,
Background: Stage III non-small cell lung cancer (NSCLC) is a highly heterogeneous stage due to its subgroups (IIIA-IIIC) comprising both resectable and unresectable tumors. Accurate determination of the extent of the disease is essential for excluding stage IV and choosing the optimal treatment regimen. Whole body positron emission tomography and computed tomography scan (PET/CT) is recommended as an initial staging imaging in locally advanced NSCLC.
View Article and Find Full Text PDFArticle Synopsis
- Pediatric OCD is a serious mental health condition that can be hard to treat, and about 10% of kids don't get better with standard treatments.
- Researchers looked at different ways to help those kids who don't respond to normal treatments, including learning from studies done on adults.
- The most promising options for treating these kids include special intensive programs and using certain medications alongside antidepressants, but more research is needed to find the best solutions.
Article Synopsis
- A phase 3 trial found that neoadjuvant treatment with nivolumab plus chemotherapy improved event-free survival in patients with resectable non-small-cell lung cancer (NSCLC) compared to chemotherapy alone, with 70.2% of the nivolumab group remaining event-free at 18 months, versus 50.0% in the chemotherapy group.!* -
- Patients receiving nivolumab also had a significantly higher rate of pathological complete response (25.3%) compared to those on chemotherapy (4.7%), indicating better treatment efficacy.!* -
- The safety profile was similar between both groups, with 32.5% of nivolumab patients experiencing grade 3 or 4 treatment-related adverse events
Article Synopsis
- Treatment strategies for advanced stage non-small cell lung cancer (NSCLC) have evolved significantly with the introduction of targeted therapies and immunotherapy.
- The growth of targeted therapies in oncology includes the identification of primary mutations, co-occurring mutations, and resistance mechanisms that influence treatment decisions.
- Implementing large-panel next-generation sequencing (NGS) for all patients is essential, and centralized expert laboratories are recommended for efficient predictive molecular testing and to facilitate complex clinical decision-making through a regional Molecular Tumor Board.